Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This stock

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Apr 28, 2021 9:24am

125 Views

Post# 33081354

RE:RE:RE:RE:RE:RE:RE:This stock

woundedknee wrote: I agree 100%. And I also agree with your assessment on the almagamation. That one thing alone could hold the key for a change in sentiment. gl

Agreed.
As we head into May ... we know amalgamation is only days away.
Does it happen on its own or is it combined with other news that drown out the negativity and highlight why its being done?

All to be determined ... but ... just around the corner (as per Dan's conference comments).

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing